Baidu has licensed its algorithm for messenger RNA (mRNA) sequencing to Sanofi SA, the Chinese tech giant's first commercial deal with a global drugmaker.
Sanofi, which was beaten by BioNTech/Pfizer and Moderna in the race to develop COVID-19 vaccines, plans to use the technology to design vaccine and therapeutic products for other infectious diseases.
The algorithm can generate a large number of optimized mRNA sequences.
Baidu's Huang Liang cited research indicating the algorithm could be more suitable for vaccine and therapeutic drug development than standard algorithms.
Said Huang, "The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with [the] Baidu algorithm into clinical trials and to the market."
View Full Article
Abstracts Copyright © 2021 SmithBucklin, Washington, DC, USA